Last reviewed · How we verify

NCT06018948

Effect of Two Different Doses of Dexmedetomidine Infusion in Morbidly Obese Patients

Completed Phase 4 Last updated 31 August 2023
What this trial tests

Phase 4 trial testing Dexmedetomidine 0.6 in Anesthesia in 90 participants. Completed in 30 September 2021.

Timeline
1 September 2019
Primary endpoint
30 September 2021
30 September 2021

Quick facts

Lead sponsorTanta University
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment90
Start date1 September 2019
Primary completion30 September 2021
Estimated completion30 September 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

Adults 18 to 50, any sex, with Anesthesia or Obesity, Morbid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Compare the effects of two different doses of dexmedetomidine infusion on oxygenation as a primary outcome and on lung mechanics, quality of recovery and perioperative analgesia as secondary outcomes in morbidly obese patients with restrictive lung disease undergoing abdominal surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anesthesia

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06018948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing